When Surfactants Become the Source of Particles
Every injectable biologic depends on surfactants to survive the journey from vial to patient. Polysorbate 20, Polysorbate 80, and Poloxamer 188 shield therapeutic proteins from the mechanical and interfacial stresses of filling, freezing, shipping, and reconstitution. Without them, proteins adsorb to container surfaces, unfold at air-water interfaces, and aggregate into particles that compromise both safety and efficacy.
But what happens when the protector becomes the problem? Over the past decade, the biopharmaceutical industry has confronted an uncomfortable reality: the very surfactants chosen to prevent particle formation can themselves generate visible and subvisible particles through distinct degradation pathways. For visual inspection professionals, this creates a detection challenge that demands specific knowledge of particle origins, morphologies, and timelines.
This article examines the two primary mechanisms by which surfactant-related particles form in protein drug products, the analytical evidence behind each pathway, and the practical consequences for designing robust visual inspection programs.
Enzymatic Hydrolysis of Polysorbates: A Sub-PPM Threat
Polysorbate 20 and Polysorbate 80 are fatty acid esters — their molecular architecture includes ester bonds that give them their amphiphilic character and surface-active properties. These same ester bonds, however, are substrates for lipase enzymes. The problem is not contamination from external sources; it is the residual host cell proteins (HCPs) that co-purify with the therapeutic protein during downstream manufacturing.
The mechanism is straightforward in principle but devastating in practice: trace lipases cleave polysorbate ester bonds, liberating free fatty acids (FFAs) into the aqueous formulation. As the drug product sits in storage — often for months or years at 2–8°C — FFA concentrations gradually rise. Once they exceed their aqueous solubility limit, they precipitate as insoluble particles with characteristic needle-like or plate-like morphologies [1].
What makes this pathway so challenging to control is the extraordinary potency of the enzymes involved. Zhang et al. (2020) demonstrated that liver carboxylesterase B (CES-1L), present at less than 20 ppm total HCP as measured by ELISA, could drive rapid PS80 degradation within just 18 hours at 5°C [2]. Other enzymes — including lysosomal phospholipase A2 (LPLA2) and PAF acetylhydrolase (PLA2G7) — have been identified at sub-ppm concentrations in drug substances that subsequently failed stability testing [1].
Multiple Enzymes, No Single Solution
Research has now identified at least eight distinct CHO-derived enzymes capable of hydrolyzing polysorbates in biotherapeutic formulations. This multiplicity is the core of the problem. Chiu et al. (2017) engineered a CHO cell line with lipoprotein lipase (LPL) genetically knocked out, achieving greater than 95% reduction in LPL expression. Yet polysorbate degradation in the resulting drug substance decreased by only 41–57% [3]. The remaining degradation was driven by other lipases — lysosomal acid lipase (LAL), PLBD2, LPLA2, and others — each with its own substrate preferences and purification behavior.
Compounding the difficulty, many of these lipases share physicochemical properties with the therapeutic monoclonal antibodies they contaminate. They bind to Protein A resins, elute in similar salt gradients, and resist removal by standard polishing chromatography steps. As Mathaes (2024) noted in the PDA Letter, common indicators of lipase-mediated degradation include two-step downstream processes lacking dedicated polishing steps, immediate or accelerated visible particle formation on stability, and protein concentration-dependent degradation rates [4].
Scale of the Problem — and a Measured Perspective
An industry-wide survey by Wuchner et al. (2022), encompassing responses from major biopharmaceutical manufacturers, quantified the prevalence of this challenge [5]:
| Observation During Stability Studies | Percentage of Companies Affected |
|---|---|
| Decrease in polysorbate content | 65% |
| Increase in free fatty acid levels | 50% |
| Formation of subvisible particles | 46% |
| Formation of visible particles | 38% |
These are not edge cases. However, a follow-up industry survey by Wuchner et al. (2026) involving 15 biopharmaceutical companies and 23 drug products in clinical development provides important context: while significant polysorbate content reductions were observed during long-term storage at 2–8°C, this decline did not impact critical quality attributes in the majority of cases. Fatty acid-related subvisible particles formed in 7 of 23 products, and visible particles in only 1. The authors concluded that "polysorbate degradation is considered manageable and not problematic under practical conditions," provided that appropriate control strategies are in place [14]. Corrective measures — such as downstream purification optimization or reformulation — were undertaken only when subvisible particle levels exceeded acceptable thresholds.
This nuanced view does not diminish the importance of the challenge for visual inspection. Rather, it underscores that the issue is one of control strategy rather than inevitability — and that visual inspection serves as a critical final verification that those control strategies are working.
Poloxamer 188 and the Silicone Oil Interface Problem
The vulnerability of polysorbates to enzymatic attack has driven significant interest in Poloxamer 188 (P188) as an alternative surfactant. P188 is a triblock copolymer of polyethylene oxide and polypropylene oxide (PEO-PPO-PEO) that contains no ester bonds whatsoever. This structural feature renders it completely immune to hydrolytic enzymes — eliminating the fatty acid particle pathway entirely [6].
P188 is not experimental. It is already formulated in 23 approved biological drug products, including obinutuzumab (Gazyva), abatacept (Orencia), emicizumab (Hemlibra), satralizumab (Enspryng), and somatropin (Norditropin) [7]. However, the transition from polysorbates to P188 has revealed a different particle formation mechanism — one tied to the container-closure system rather than the surfactant's chemical stability.
Protein-PDMS Aggregate Formation
Grapentin et al. (2020) first characterized a phenomenon specific to P188 formulations: the formation of visible particles composed of aggregated complexes of protein and polydimethylsiloxane (PDMS) — the silicone oil used to lubricate glass vial surfaces and syringe barrels [8]. These protein-PDMS particles were observed in monoclonal antibody formulations stored in siliconized glass vials, while equivalent formulations containing polysorbate 20 or 80 remained particle-free under identical conditions.
Soeda et al. (2023) elucidated the mechanism: therapeutic proteins adsorb to the PDMS coating on container surfaces, and in the vicinity of these silicone oil interfaces, protein-PDMS aggregates nucleate and grow into visible particles [9]. The fundamental issue is competitive adsorption. Kannan et al. (2021) demonstrated that P188 is significantly less effective than polysorbate 20 at competing with monoclonal antibodies for adsorption at silicone oil-water interfaces [10]. Polysorbates rapidly coat hydrophobic surfaces and physically exclude proteins from contact; P188's larger molecular structure and different adsorption kinetics leave proteins partially exposed.
Material Attribute Variability
A further complication is that P188 lot-to-lot variability directly influences particle formation risk. Soeda et al. (2022) demonstrated that the hydrophobicity of P188 — measured by reversed-phase HPLC — varies between commercial lots even when all lots meet pharmacopeial specifications. Critically, formulations prepared with P188 lots exhibiting higher hydrophobicity showed reduced proteinaceous visible particle formation [11]. This identifies P188 hydrophobicity as a potential Critical Material Attribute (CMA) requiring incoming material qualification beyond compendial testing.
Oxidative Degradation Under Storage
P188 also faces chemical stability concerns distinct from polysorbates. Chen et al. (2022) demonstrated that P188 undergoes auto-oxidation in liquid formulations, with the rate depending on buffer composition. Histidine buffer — widely used in monoclonal antibody formulations — can promote P188 degradation in the presence of hydroxyl radicals, generating peroxide species that pose a secondary risk of protein oxidation during long-term storage [12].
What This Means for Visual Inspection
Both surfactant degradation pathways ultimately produce particles that must be detected during 100% visual inspection of injectable drug products. Under USP <790> and the FDA's 2021 guidance on inspection of injectable products for visible particulates, products must be "essentially free" of visible particulate matter [13]. There is no regulatory threshold below which visible particles become acceptable — they are regarded as contamination regardless of origin.
However, surfactant-related particles present distinct detection challenges compared to extrinsic contaminants like fibers, glass fragments, or metal particles:
Fatty Acid Particles from Polysorbate Degradation
Free fatty acid precipitates typically appear as translucent needles or thin plates with low refractive index contrast against the aqueous formulation. Unlike opaque foreign particles that scatter light strongly, FFA particles may be visible only under specific lighting angles or during the swirl-and-inspect motion. Their translucency makes them particularly challenging for automated visual inspection (AVI) systems optimized for high-contrast defects. Additionally, different fatty acid species have different solubility limits — lauric acid (C12) from PS20 degradation precipitates at lower concentrations than oleic acid (C18:1) from PS80 — meaning the particle morphology and detection difficulty varies by polysorbate type [1].
Recent work by Koulov et al. (2023) demonstrated that machine learning approaches — specifically convolutional neural networks applied to flow imaging microscopy data — can reliably classify subvisible particles as originating from polysorbate degradation (free fatty acids), protein aggregation, or silicone oil, based on morphological features [15]. This type of analytical capability is increasingly important for root cause investigations when particles are detected during inspection, as it enables rapid differentiation between surfactant-related and process-related particle sources.
Protein-PDMS Particles from P188 Formulations
Protein-silicone oil aggregates present as irregular, often translucent masses that may resemble inherent protein particles or air bubbles depending on their size and composition. Differentiating between acceptable silicone oil droplets (present in all siliconized containers) and unacceptable protein-PDMS aggregates requires inspector training with representative defect standards. The challenge is compounded by the fact that these particles form progressively during storage — a unit that passes inspection at release may develop visible particles months later during its shelf life.
Reassessing What "Visible" Means
The detection of surfactant-related particles also intersects with fundamental questions about particle visibility thresholds. Koulov et al. (2023) reassessed the size thresholds and other particle characteristics that define visibility during manual inspection of parenteral products, finding that factors beyond size — including refractive index contrast, morphology, and background formulation properties — significantly influence whether a given particle is detectable under standard inspection conditions [16]. For translucent FFA needles and protein-PDMS aggregates, this means that the commonly cited "100 μm visibility threshold" may substantially underestimate the detection challenge.
Progressive Formation and Stability Implications
Unlike extrinsic contamination, which is typically introduced during manufacturing and remains constant, surfactant-related particles form progressively over time. This has direct implications for inspection program design:
- Release inspection alone is insufficient — stability monitoring must include visual assessment at defined intervals
- Accelerated stability conditions may not accurately predict particle formation rates at long-term storage temperatures
- Returned goods and complaint investigations must consider time-dependent particle formation as a root cause
Designing Inspection Programs for Surfactant-Related Particles
For manufacturers whose products contain polysorbates or P188, the visual inspection program must be designed with explicit awareness of the particle types that may form. This requires alignment between formulation scientists, analytical development, and quality control inspection teams.
Inspector Qualification
Knapp test sets used for inspector qualification should include challenge units containing particles representative of surfactant degradation products — not only the standard fiber, glass, and metal defects. For polysorbate-containing products, this means translucent, low-contrast particles at the detection threshold. For P188 products in siliconized containers, this means protein-aggregate particles that challenge the inspector's ability to distinguish them from acceptable silicone oil droplets.
AVI/SAVI Recipe Development
Automated and semi-automated inspection systems must be validated against the specific particle types relevant to the product's surfactant strategy. Recipe parameters optimized for detecting opaque foreign particles may lack sensitivity for translucent fatty acid needles or protein-PDMS aggregates. Surrogate solutions matched to the product's refractive index, viscosity, and density ensure that detection sensitivity measured during validation is representative of actual inspection conditions.
Analytical Bridging
A robust control strategy bridges formulation monitoring with inspection outcomes. The analytical toolbox for polysorbate testing — as described by Mathaes (2024) — combines routine quantification methods with extended characterization techniques that inform inspection decisions [4]:
| Analytical Method | What It Measures | Inspection Program Relevance |
|---|---|---|
| Fluorescence Micelle Assay (FMA) | Polysorbate concentration | Predicts when surfactant loss will reach critical levels |
| HPLC-CAD / ELSD | Polysorbate degradation profile | Identifies degradation before particles become visible |
| Lipolytic Activity Assay | Residual lipase activity in drug substance | Risk-stratifies batches for enhanced inspection monitoring |
| Flow Imaging Microscopy (MFI) | Subvisible particle morphology and count | Bridges gap between subvisible data and visible inspection |
| FTIR Microscopy | Chemical identity of isolated particles | Confirms root cause when visible particles are found |
| Mass Spectrometry (HPLC-MS) | Fatty acid profiling and oxidative degradants | Distinguishes enzymatic from oxidative degradation mechanism |
The correlation between lipolytic activity testing and stability outcomes is particularly valuable: if residual lipase activity is detected in the drug substance, batches can be flagged for enhanced inspection monitoring during stability — even before particles become visible [4].
The Path Forward
Neither polysorbates nor Poloxamer 188 offer a particle-free guarantee. Polysorbates remain the most widely characterized and best-understood surfactants for protein stabilization, supported by decades of clinical experience — but their susceptibility to enzymatic degradation demands rigorous HCP control, analytical monitoring, and inspection vigilance. P188 eliminates the enzymatic pathway entirely but introduces container-closure compatibility challenges and material attribute variability that require their own control strategies.
A 2025 industry survey by Thakral et al. confirmed that while P188 adoption is growing, the pharmaceutical industry's position on surfactant alternatives remains unsettled [7]. The choice must be made product by product, weighing the specific protein's interfacial behavior, the downstream process capability for HCP clearance, the container-closure system, and the target shelf life.
For those of us in visual inspection, the practical takeaway is this: knowing which surfactant a product contains tells you what kinds of particles to expect, when they might appear, and how difficult they will be to detect. That knowledge must flow directly into test kit design, inspector training curricula, AVI recipe parameters, and stability inspection protocols. The surfactant strategy is not just a formulation decision — it is an inspection program design input.
References
- Felix T, Kuschmierz LK, Zeh L, Diel B, Fischer S, Hartl J, Hofer T, Maa Y-F, Metzger P, Muehl H, Plesker R, Roesch M, Schoenfeld D, Stracke JO, Wuchner K, Zürcher A, Heindl D. Polysorbates degrading enzymes in biotherapeutics — a current status and future perspectives. Front Bioeng Biotechnol. 2025;12:1490276.
- Zhang S, Xiao H, Molden R, Qiu H, Li N. Rapid polysorbate 80 degradation by liver carboxylesterase in a monoclonal antibody formulated drug substance at early stage development. J Pharm Sci. 2020;109(9):2793–2801.
- Chiu J, Valente KN, Levy NE, Lipsmeier F, Erdmann S, Jameel F, Robinson AS, Ryll T. Knockout of a difficult-to-remove CHO host cell protein, lipoprotein lipase, for improved polysorbate stability in monoclonal antibody formulations. Biotechnol Bioeng. 2017;114(5):1006–1015.
- Mathaes R. Current challenges and control strategies for polysorbates in biopharmaceuticals. PDA Letter. January 30, 2024.
- Wuchner K, Yi L, Grapentin C, et al. Industry perspective on the use and characterization of polysorbates for biopharmaceutical products Part 1: Survey report on current state and common practices for handling and testing of polysorbates. J Pharm Sci. 2022;111(11):2955–2981.
- Bollenbach L, Buske J, Oehme M, Goerke J, Trenkel M, Paulus G, Kolter K. Poloxamer 188 as surfactant in biological formulations — an alternative for polysorbate 20/80? Int J Pharm. 2022;620:121706.
- Thakral S, Agrahari V, Engstrom J, et al. A pharmaceutical industry survey results on exploring polysorbate alternatives in biological drug products: poloxamer and other surfactants. J Pharm Sci. 2025.
- Grapentin C, Müller C, Kishore RSK, Adler M, ElBialy I, Kappenstein O, Wenzel M, Friess W. Protein-polydimethylsiloxane particles in liquid vial monoclonal antibody formulations containing poloxamer 188. J Pharm Sci. 2020;109(8):2393–2404.
- Soeda Y, Matsumoto M, Uchiyama S. Mechanism of protein–PDMS visible particles formation in liquid vial monoclonal antibody formulation. J Pharm Sci. 2023;112(3):735–745.
- Kannan A, Shieh IC, Leiske DL, Fuller GG. Adsorption and aggregation of monoclonal antibodies at silicone oil–water interfaces. Mol Pharmaceutics. 2021;18(4):1656–1665.
- Soeda Y, Matsumoto M, Uchiyama S. Impact of poloxamer 188 material attributes on proteinaceous visible particle formation in liquid monoclonal antibody formulations. J Pharm Sci. 2022;111(9):2519–2528.
- Chen Y, Kuzmanovic D, Bhargava R, Bhatt R. The degradation of poloxamer 188 in buffered formulation conditions. AAPS Open. 2022;8:5.
- U.S. Food and Drug Administration. Inspection of injectable products for visible particulates: guidance for industry. December 2021.
- Wuchner K, Bleher S, Wiggers F, Krishnamachari Y, Prajapati I, et al. Do we worry too much about polysorbate degradation? An industry-wide perspective with real-life case studies. J Pharm Sci. 2026;115(1).
- Koulov AV, Kirschenbühler K, Drewes S. Image classification of degraded polysorbate, protein and silicone oil sub-visible particles detected by flow-imaging microscopy in biopharmaceuticals using a convolutional neural network. J Pharm Sci. 2023;112(10):2609–2618.
- Koulov AV, et al. Monitoring of visible particles in parenteral products by manual visual inspection — reassessing size threshold and other particle characteristics that define particle visibility. J Pharm Sci. 2023;112(12):3075–3085.
